About Adam Feldman
Dr. Feldman earned a BA degree in the Biological Basis of Behavior from the University of Pennsylvania, an MA degree from Boston University School of Medicine, an MD degree from the University of Massachusetts, and he is currently earning his MPH degree at Harvard School of Public Health. He completed training in urologic oncology at Massachusetts General Hospital and is currently an Assistant Professor of Urology and Surgery at the Massachusetts General Hospital.
Novel biomarkers for improved detection and prognosis of prostate cancer are needed. Intracellular, membrane-associated and secreted proteins are differentially expressed by prostate cancer cells as compared to benign prostate cells. Dr. Feldman proposes to discover these differentially expressed proteins in urine, a non-invasive practical biological fluid for biomarker discovery. The second goal of this project is to correlate biomarker findings with prostate cancer diagnosis, grade and pathologic stage.
Matthew Smith, MD, PhD, of the MGH Cancer Center, is a world leader in prostate cancer clinical investigations for bone stability and improved survivorship in patients on hormonal therapy, and Bruce Zetter, PhD, a world-leading cancer biologist at Harvard Medical School, will serve as Dr. Feldman’s co-mentors.
The 2008 Michael and Lori Milken – PCF Young Investigator Award
Adam Feldman, MD
Massachusetts General Hospital Cancer Center – Boston, MA